RT Journal Article
SR Electronic
T1 Changes in monocyte subsets can predict the risk of AAA and are surrogate markers for AAA morphology in patients with late-stage disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.18.24317518
DO 10.1101/2024.11.18.24317518
A1 Hamann, Bianca
A1 Klimova, Anna
A1 Kapalla, Marvin
A1 Poitz, David M.
A1 Frank, Frieda
A1 Morawietz, Henning
A1 Reeps, Christian
A1 Hofmann, Anja
YR 2024
UL http://medrxiv.org/content/early/2024/11/19/2024.11.18.24317518.abstract
AB Background Monocytes play a pivotal role in pathology of abdominal aortic aneurysm (AAA) and can display an immunophenotypic heterogeneity with functionally distinct subpopulations. Alterations in monocyte subsets have been described in CVD, and some are associated with cardiovascular risk, but their profile in AAA is poorly understood.Aim We aimed to comprehensively define associations of circulating monocyte phenotypes with AAA risk and AAA morphology.Methods Monocyte subsets (CD14++CD16−; CD14++/CD16+; CD14+/CD16++) were analyzed in a prospective, observational study in patients with AAA (n=34) and varicose veins (n=34) by using flow cytometry.Results Classical monocytes were 1.6-fold lower (P=0.001) in AAA, while intermediate and non-classical monocytes were 1.8 (P=0.019) and 1.9-fold (P=0.025) higher in AAA, respectively. The differences remained significant after adjusting for age, sex and peripheral artery disease. A lower proportion of classical monocytes (HR: 0.73, P=0.002) and increases in intermediate (HR: 1.41, P=0.006) and non-classical monocytes (HR: 1.54, P=0.030) were associated with a higher risk of AAA. Non-classical monocytes showed an inverse correlation with AAA diameter (Pearson correlation =-0.64, P=0.001) and AAA volume (Pearson correlation =-0.50, P=0.003).Conclusion The present study revealed age- and sex-independent shifts in monocytes, all of which were associated with risk of AAA disease. Non-classical monocytes were inversely correlated with AAA diameter and volume and thus may be surrogate markers for AAA morphology.What’s new?Classical monocytes are lower in patients with late-stage AAA.Non-classical monocytes showed the strongest increase in AAA disease.A reduction in classical monocytes is associated with increased risk of AAA.An increase in non-classical and intermediate monocytes is associated with an increased risk of AAA.Lowering in non-classical monocytes may be a surrogate marker for AAA morphology, particlarly AAA volume.Intermediate monocytes showed a positive correlation with the thickness of the intraluminal thrombus.What are the clinical implications?The increase in non-classical monocytes could be a novel surrogate marker for AAA volume, which could be useful when AAA diameter is insufficient or to monitor a saccular AAA, as there is a weaker correlation between diameter and risk of rupture in this type of AAA.The decrease in classical monocytes could be a useful surrogate marker for AAA volume and provide additional information on AAA diameter.Monocyte shifts and their association with AAA disease may be relevant for the diagnosis of AAA and should be verified in larger cohorts.The mechanisms behind the decrease in classical monocytes and the increase in intermediate and non-classical subsets should be investigated in further in vitro studies as they offer therapeutic potential.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study is a basic science study.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of the Technische Universität Dresden (EK 151042017).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data are published within the manuscript.AAAabdominal aortic aneurysmACEangiotensin-converting enzymeARBsangiotensin receptor blockerASAacetylsalicylic acidBMIbody mass indexCADcoronary artery diseaseCAScarotid artery stenosisCCBcalcium channel blockerCVDcardiovascular diseaseHbhemoglobinHDLhigh-density lipoprotein cholesterolHFheart failureLDLlow-density lipoprotein cholesterolPADperipheral artery diseaseT2DType 2 diabetes mellitusTCtotal cholesterol